Correlation Between Allogene Therapeutics and Karyopharm Therapeutics

Can any of the company-specific risk be diversified away by investing in both Allogene Therapeutics and Karyopharm Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Allogene Therapeutics and Karyopharm Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Allogene Therapeutics and Karyopharm Therapeutics, you can compare the effects of market volatilities on Allogene Therapeutics and Karyopharm Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Allogene Therapeutics with a short position of Karyopharm Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Allogene Therapeutics and Karyopharm Therapeutics.

Diversification Opportunities for Allogene Therapeutics and Karyopharm Therapeutics

0.16

Correlation Coefficient

Allogene Therapeutics  Karyopharm Therapeutics

Average diversification

The 3 months correlation between Allogene and Karyopharm is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Allogene Therapeutics and Karyopharm Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Karyopharm Therapeutics and Allogene Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Allogene Therapeutics are associated (or correlated) with Karyopharm Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Karyopharm Therapeutics has no effect on the direction of Allogene Therapeutics i.e., Allogene Therapeutics and Karyopharm Therapeutics go up and down completely randomly.

Pair Corralation between Allogene Therapeutics and Karyopharm Therapeutics

Given the investment horizon of 90 days Allogene Therapeutics is expected to generate 3.31 times less return on investment than Karyopharm Therapeutics. In addition to that, Allogene Therapeutics is 1.02 times more volatile than Karyopharm Therapeutics. It trades about 0.02 of its total potential returns per unit of risk. Karyopharm Therapeutics is currently generating about 0.07 per unit of volatility. If you would invest  72.00  in Karyopharm Therapeutics on September 3, 2024 and sell it today you would earn a total of  13.00  from holding Karyopharm Therapeutics or generate 18.06% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Allogene Therapeutics  vs.  Karyopharm Therapeutics

Allogene Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Allogene Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Allogene Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Karyopharm Therapeutics

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Karyopharm Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Karyopharm Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Allogene Therapeutics and Karyopharm Therapeutics

The main advantage of trading using opposite Allogene Therapeutics and Karyopharm Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Allogene Therapeutics position performs unexpectedly, Karyopharm Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Karyopharm Therapeutics will offset losses from the drop in Karyopharm Therapeutics' long position.

The idea behind Allogene Therapeutics and Karyopharm Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..